Jinling Pharmaceutical Company Limited (SHE:000919)

Market Cap	4.55B +9.4%
Revenue (ttm)	3.16B -2.6%
Net Income	58.94M +33.4%
EPS	0.09 +27.1%
Shares Out	621.92M
PE Ratio	77.27
Forward PE	n/a
Dividend	0.10 (1.37%)
Ex-Dividend Date	Jul 8, 2025

Volume	21,795,200
Average Volume	65,031,956
Open	7.36
Previous Close	7.30
Day's Range	7.18 - 7.37
52-Week Range	6.35 - 9.80
Beta	0.43
RSI	44.96
Earnings Date	Mar 31, 2026

About SHE:000919

Jinling Pharmaceutical Company Limited, together with its subsidiaries, manufactures and sells pharmaceuticals and medical devices in China and internationally. It offers Mailuoning injection and oral solution for the treatment of thromboangiitis and arteriosclerosis obliterans, as well as cerebral and venous thrombosis; Sulifei, a ferrous succinate tablet for the prevention and treatment of iron deficiency anemia; Lentinan injection, an adjuvant therapy for the treatment of malignant tumors; and absorbable gelatin sponges for the treatment of ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 5,789
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000919

Financial Performance

In 2025, SHE:000919's revenue was 3.20 billion, a decrease of -2.56% compared to the previous year's 3.28 billion. Earnings were 53.91 million, an increase of 33.42%.